14 December 2022 | News
Aims to become a 'total healthcare solution provider' as it strengthens its digital business ecosystem under 'Project Zero'
Image caption- Sun Gwan Hwang, Vice President of SK Biopharmaceuticals’ R&D Innovation
South Korea-based SK Biopharmaceuticals has introduced its roadmap and vision for its digital healthcare business. SK Biopharmaceuticals said under the so-called "Project Zero'," it aims to become a "total healthcare solution provider" by optimising its digital business model and ecosystem.
The project includes the development of wearable devices converged with artificial intelligence (AI) and mobile technologies that can offer real-time monitoring and data-driven seizure detection for patients with epilepsy.
The devices under development are: "Zero Glasses," "Zero Wired," "Zero Headband," "Zero Earbud" and "Zero Headset." These wearable devices are all compatible with the "Zero AppT" that can record seizures and gather bio-signal data in real time, which can be sent for analysis. The name of the project derives from the company's key mission to strive for the potential of "zero seizures" for patients.
SK Biopharmaceuticals said it will expand beyond the central nervous system to provide digital healthcare solutions for patients with other disorders including cancer, as it moves forward with the project.